Table 3.
Patient and tumor characteristics relative to neoadjuvant or adjuvant chemotherapy status in the group of patients receiving chemotherapy
| Characteristics | Total, n (%) | Chemotherapy, n (%) |
p value | |
|---|---|---|---|---|
| neoadjuvant | adjuvant | |||
| Age, years | ||||
| <50 | 61 (100) | 19 (31.1) | 42 (68.9) | < 0.001 |
| 50–65 | 856 (100) | 200 (23.4) | 656 (76.6) | |
| >65 | 548 (100) | 74 (13.5) | 474 (86.5) | |
| Total, n | 1,465 | 293 | 1,172 | |
| BMI, kg/m2 | ||||
| <20 | 50 (100) | 12 (24.0) | 38 (76.0) | 0.027 |
| 20–25 | 447 (100) | 103 (23.0) | 344 (77.0) | |
| 25–30 | 572 (100) | 109 (19.1) | 463 (80.9) | |
| >30 | 388 (100) | 67 (17.3) | 321 (82.7) | |
| Total, n | 1,457 | 292 | 1,166 | |
| ECOG | ||||
| 0 or 1 | 1,414 (100) | 281 (19.9) | 1,133 (80.1) | 0.521 |
| >1 | 51 (100) | 12 (23.5) | 39 (76.5) | |
| Total, n | 1,465 | 2,456 | 1,465 | |
| Grading | ||||
| 1 | 75 (100) | 12 (16.0) | 63 (84.0) | 0.611 |
| 2 | 977 (100) | 199 (20.4) | 778 (79.6) | |
| 3 | 402 (100) | 77 (19.2) | 325 (80.8) | |
| Total, n | 1,454 | 288 | 1,166 | |
| HER2 | ||||
| Negative | 1,178 (100) | 235 (19.9) | 943 (80.1) | 0.942 |
| Positive | 283 (100) | 57 (20.1) | 226 (79.9) | |
| Total, n | 1,461 | 292 | 1,169 | |
| Concomitant medication, n | ||||
| 0 | 696 (100) | 139 (20.0) | 557 (80.0) | 0.438 |
| 1 | 227 (100) | 48 (21.1) | 179 (78.9) | |
| 2 | 157 (100) | 33 (21.0) | 124 (79.0) | |
| 3 | 116 (100) | 31 (26.7) | 85 (73.3) | |
| ≥4 | 270 (100) | 42 (15.6) | 228 (84.4) | |
| Total, n | 1,466 | 293 | 1,171 | |
| Concomitant diseases, n | ||||
| 0 | 556 (100) | 118 (21.2) | 438 (78.8) | 0.074 |
| 1 | 412 (100) | 91 (22.1) | 321 (77.9) | |
| 2 | 262 (100) | 47 (17.9) | 215 (82.1) | |
| 3 | 136 (100) | 18 (13.2) | 118 (86.8) | |
| ≥4 | 100 (100) | 19 (19.0) | 81 (81.0) | |
| Total, n | 1,466 | 293 | 1,173 (100) | |
BMI = Body mass index; ECOG = Eastern Cooperative Oncology Group.